FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Cohen Martin H,Shen Yuan Li,Keegan Patricia,Pazdur Richard. The Oncologist . 2009Cohen MH, Shen YL, Keegan P, et al. FDA drug approval summary: bevacizumab (Avastin) as treatment of...
Bevacizumabis FDA-approved for variety of indications:metastatic colorectal cancer(in combination with afluorouracilbased regimen),glioblastoma(asmonotherapyor in combination with irinotecan), metastatic non-small cell lung cancer (NSCLC) of the nonsquamous cell histopathological subtype (in combination with...
Earlier this year, the US Food and Drug Administration (FDA) granted accelerated approval for bevacizumab, making it the first drug to be approved for recurrent glioblastoma in more than a decade, asreportedbyMedscape Oncology. It is also the first systemic therapy to be approved for recurrent ...
Avastin is indicated for the treatment of recurrent glioblastoma in adults. First-line non-squamous non-small cell lung cancer (NSCLC) Avastin, in combination with carboplatin and paclitaxel, is indicated for the first‑line treatment of patients with unresectable, locally advanced, recurrent or met...
Food and Drug Administration (FDA) has approved Vegzelma® (bevacizumab-adcd), a biosimilar to Avastin® (bevacizumab)[1], for the treatment ofsix types of cancer: metastatic colorectal cancer; recurrent or metastatic non-squamous non-small cell lung cancer (nsNSCLC); recurrent glioblastoma;...
SUGGESTED for you In May 2009, the FDA grantedaccelerated approvalfor bevacizumab for use in patients with glioblastoma that has progressed despite previous therapy. Bevacizumab has also been approved for use in Japan,but not in Europe, except in Switzerland and Rumania. This is the first drug to...
20 2007, Dr Timothy Cloughesy of the UCLA Neuro-Oncology Program, presented data showing half of patients with relapsed glioblastoma multiforme [Primary Brain Tumor] survived for six months without disease progression when treated with bevacizumab (Avastin) and irinotecan (Campto) These results were ...
approval for the use of bevacizumab for the treatment of patients with metastatic renal cell carcinoma and glioblastoma, and in Europe, it is also approved in metastatic breast cancer in combination with paclitaxel. Bevacizumab is under investigation in the first-line and adjuvant setting of almost ...
Epidermal growth factor receptor; EMA: European Medicines Agency; FDA: (US) Food and Drug Administration; FTC: Fallopian tube cancer; GBM: Glioblastoma; PPC: Primary peritoneal cancer; NSCLC: Non-small-cell lung cancer, Nsq-NSCLC: non-squamous non-small-cell lung cancer; RCC: Renal cell carci...
Evofosfamide (Evo or TH302) is a hypoxia-activated prodrug which is reduced leading to the release of alkylating agent bromo-isophosphoramide mustard, which has shown safety and signals of efficacy in a prior phase 1 study in recurrent glioblastoma. We p